Free Trial
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Finch Therapeutics Group logo
$13.08 -0.13 (-0.95%)
As of 11:31 AM Eastern

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Key Stats

Today's Range
$13.08
$13.08
50-Day Range
$12.30
$13.75
52-Week Range
$1.27
$15.85
Volume
509 shs
Average Volume
2,157 shs
Market Capitalization
$21.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Finch Therapeutics Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

FNCH MarketRank™: 

Finch Therapeutics Group scored higher than 8% of companies evaluated by MarketBeat, and ranked 923rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Finch Therapeutics Group.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Finch Therapeutics Group is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Finch Therapeutics Group is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Finch Therapeutics Group has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.10% of the float of Finch Therapeutics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Finch Therapeutics Group has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Finch Therapeutics Group does not currently pay a dividend.

  • Dividend Growth

    Finch Therapeutics Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.10% of the float of Finch Therapeutics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Finch Therapeutics Group has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • MarketBeat Follows

    Only 1 people have added Finch Therapeutics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Finch Therapeutics Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.77% of the stock of Finch Therapeutics Group is held by institutions.

  • Read more about Finch Therapeutics Group's insider trading history.
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Stock News Headlines

FNCH Finch Therapeutics Group, Inc. - Seeking Alpha
Arquitos Capital's Largest Holdings For Q1 2025
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Arquitos Capital Management Q4 2024 Commentary
Finch Therapeutics announces Nasdaq delisting, SEC deregistration
Finch Therapeutics Group to Delist from Nasdaq
Finch Announces Delisting from Nasdaq and SEC Deregistration
See More Headlines

FNCH Stock Analysis - Frequently Asked Questions

Finch Therapeutics Group's stock was trading at $11.30 at the beginning of the year. Since then, FNCH shares have increased by 15.7% and is now trading at $13.0750.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($6.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($12.60) by $6.30. The firm earned $11.34 million during the quarter.

Shares of Finch Therapeutics Group reverse split on Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
11/10/2021
Today
7/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FNCH
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.75 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$110 thousand
Price / Cash Flow
N/A
Book Value
$14.25 per share
Price / Book
0.92

Miscellaneous

Free Float
885,000
Market Cap
$21.00 million
Optionable
No Data
Beta
1.26
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:FNCH) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners